Lv4
510 积分 2024-02-21 加入
Efficacy and Safety of Switching to Picankibart from Non-interleukin-23 Subunit p19 Inhibitors in Patients with Plaque Psoriasis: A Multicenter, Open-Label, Phase 2 Trial
14小时前
待确认
75120 Efficacy of Picankibart among Difference BMI and Body Weight in Adult Plaque Psoriasis: Subgroup Analyses of the Phase 3 CLEAR-1 Trial
1个月前
已关闭
Unveiling the effectiveness and safety spectrum of biologic therapies in psoriasis: a three-year real-world analysis
1个月前
已完结
Clarifying psoriasis disease severity: A position statement from the National Psoriasis Foundation Medical Board
1个月前
已完结
61865 Guselkumab demonstrates effectiveness regardless of disease duration: Week 76 results from the real-world G-EPOSS study
2个月前
已关闭
Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
2个月前
已完结
Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
2个月前
已完结
Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review
2个月前
已完结
Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment
2个月前
已完结
English version of Japanese guidance for use of biologics for psoriasis (the 2022 version)
2个月前
已完结
皖公网安备34019202002308
